Introduction Non-medical use of prescription opioids such as the mu opioid receptor (MOP-r) agonist oxycodone is a growing problem in the USA and elsewhere. There is limited information about oxycodone's impact on diverse gene systems in the brain. Objectives The current study was designed to examine how chronic oxycodone self-administration (SA) affects gene expression in the terminal areas of the nigrostriatal and mesolimbic dopaminergic pathways in mice. Method Adult male C57BL/6J mice underwent a 14-day oxycodone self-administration procedure (4 h/day, 0.25 mg/kg/ infusion, FR1) and were euthanized 1 h after the last session. The dorsal and ventral striata were dissected, and total RNAs were extracted. Gene expressions were examined using RNA sequencing. Result We found that oxycodone self-administration exposure led to alterations of expression in numerous genes related to inflammation/immune functions in the dorsal striatum (54 upregulated genes and 1 downregulated gene) and ventral striatum (126 upregulated genes and 15 downregulated genes), with 38 upregulated genes identified in both brain regions. Conclusion This study reveals novel neurobiological mechanisms underlying some of the effects of a commonly abused prescription opioid. We propose that inflammation/immune gene systems may undergo a major change during chronic self-administration of oxycodone.
Introduction
Over the past 15 years, there has been a dramatic increase in the medical and non-medical use of prescription opioids (short-acting mu opioid receptor (MOP-r) agonists). Oxycodone is one of the most commonly abused prescription opioids, which accounts for a substantial percentage of opioidrelated deaths in the USA (Paulozzi et al. 2015) . The effects of oxycodone are predominantly mediated initially through MOP-r (Beardsley et al. 2004 ). There is limited information about oxycodone's impact on the brain and the underlying neurobiological mechanisms involved in its abuse.
An early study (using a microarray technique) reported that repeated experimenter-administered oxycodone in rats (15 mg/kg, twice a day for 8 days) led to upregulation of 31 genes and downregulation of 25 genes, in the whole brain (Hassan et al. 2007 ). We extended this study by examining the effects of oxycodone in a mouse model of 14-day oxycodone self-administration on expression of genes in specific areas of the brain. We identified 61 genes that were Yong Zhang and Yupu Liang contributed equally to this work.
* Yong Zhang zhangyo@rockefeller.edu 1 downregulated and 18 genes that were upregulated in several brain regions in male adult and adolescent mice. Those studies focused on genes involved in neurotransmission or synaptic plasticity (Mayer-Blackwell et al. 2014; Zhang et al. 2014 Zhang et al. , 2015 . Although microarrays have been widely used in quantitative transcriptomics, these techniques have several limitations: reliance on prior knowledge about genes for probes or PCR primer design, and monitoring only some portions of the known genes. RNA sequencing (RNA-seq) has been recently introduced for transcriptome profiling based on massively parallel, unbiased sequencing. RNA-seq offers several important advantages over other gene expression technologies: it provides more accurate, sensitive, and reliable gene expression data, in addition to the detection of gene variants and alternative splicing (e.g., Goldman and Domschke 2014; Wang et al. 2014 ). However, RNA-seq technology is still in a developmental stage, and there is little consensus regarding optimal methods for quantification and downstream analysis, especially for brain tissues. In the current study, RNA-seq was used for the first time to identify changes in the genome-wide expression of transcripts in the mouse dorsal and ventral striata following 14-day extended-access (4-h) oxycodone selfadministration.
The dorsal and ventral striata (terminal regions of the nigrostriatal and mesolimbic dopaminergic pathways, respectively) are thought to mediate different aspects of reward and drug seeking (e.g., Koob and Volkow 2010; Lobo and Nestler 2011) . Numerous studies have shown that the dorsal striatum is gradually engaged in habitual and compulsive-like drug seeking (e.g., Barker and Taylor 2014; Belin et al. 2009; Everitt 2014; Everitt and Robbins 2013; Porrino et al. 2007 ). The ventral striatum plays a crucial role in processing rewarding stimuli, as well as stimulations which are both rewarding and reinforcing (e.g., Olsen 2011).
Methods Subjects
Male adult (11 weeks old on arrival) C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were housed in groups of four, with free access to food and water in a light-controlled (12:12 h light/dark cycle, lights on at 7:00 p.m. and off at 7:00 a.m.) and temperature-controlled (25°C) room. Animal care and experimental procedures were conducted according to the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources Commission on Life Sciences 2016). The experimental protocols used were approved by the Institutional Animal Care and Use Committee of the Rockefeller University. In the current study, we examined gene expression using RNA-seq in the male C57BL/6J mice because we had carried out numerous studies in this strain of male mice in the past (e.g., Mayer-Blackwell et al. 2014; Zhang et al. 2014 Zhang et al. , 2015 . Comparative studies of female mice would be of great interest for follow-up studies.
Self-administration procedure

Catheter implantation and intravenous self-administration chambers
Following acclimation for 7 days, the mice were anesthetized with a combination of xylazine (8.0 mg/kg, i.p.) and ketamine (80 mg/kg, i.p.). For details of surgical procedure and description of operant conditioning chambers, see Zhang et al. (2009 Zhang et al. ( , 2014 and Mayer-Blackwell et al. (2014) . Immediately after surgery, the surgical sutures and incision areas of all the mice studied were covered with an antibiotic ointment. No further antibiotic was used.
Oxycodone self administration
Study 1 A 4-h self-administration session was conducted once a day for 14 consecutive days. Each day, mice were weighed and heparinized saline (0.01 ml of 30 IU/ml solution) was used to flush the catheter to maintain patency. During self-administration sessions, mice were placed in the self-administration chambers and a nose poke through the active hole led to an infusion of oxycodone (0.25 mg/kg/infusion; Sigma, St. Louis, MO) under a FR1 schedule. Drug dose was adjusted on a daily basis by a computer program which took into account the changes in an animal's body weight. Mice in the saline control groups received yoked saline infusions during all sessions (saline was infused in the control mouse whenever the oxycodone mouse self-administered oxycodone). At the end of the experiment, only data from mice that passed a catheter patency test, defined as a loss of muscle tone within a few seconds after administration of 30 μl ketamine (5 mg/ml) (Fort Dodge, IA), were included in the analysis of data.
Of a total 31 mice that started in this study, 22 mice finished the 14-day self-administration sessions and passed the catheter patency test. Of these 22 mice, the brain tissues of 12 mice (6 oxycodone and 6 yoked saline controls) were randomly chosen for the RNA-seq study. These mice were studied as part of a recent publication, and detailed behavioral data are available in that publication .
Study 2 In order to have sufficient RNA for confirmation of RNA-seq data by quantitative polymerase chain reaction (qPCR), separate groups of mice underwent an identical 4-h self-administration (SA) session once a day for 14 consecutive days. Of a total 26 mice that started in the second study, 16 mice completed the 14-day SA study and passed the catheter patency test. The brain tissues from these mice (9 oxycodone and 7 yoked saline controls) were used in the qPCR confirmation study.
RNA extraction
Mice were sacrificed within 1 h after the last selfadministration session by decapitation after brief exposure to CO 2 ; the dorsal and ventral striata from each mouse were dissected from the brain and homogenized in QIAzol (Qiagen, Valencia, CA). Total RNA was isolated from the dorsal and ventral striata using the miRNeasy kit (Qiagen, Valencia, CA). The quality and quantity of RNA from each sample was determined using an Agilent 2100 Bioanalyzer.
RNA-seq library preparation and sequencing
The integrity of RNA samples was evaluated again by Agilent 6000 RNA Nano Chips. RNA-seq library preparation and sequencing of samples isolated from the dorsal striatum was performed by LC Sciences (Houston, TX) whereas RNA-seq library preparation and sequencing of RNA isolated from ventral striatum was performed by the Genomic Resource Center at the Rockefeller University. Both RNA-seq libraries were prepared using the Illumina's TruSeq ® Stranded Total RNA LT kit (with Ribo-Zero™) following the manufacturer's protocol. Briefly, starting with 100 ng total RNA, cytoplasmic ribosomal RNA was removed, and the remaining RNA was fragmented by incubating at 94°C for 8 min with divalent cations. The cleaved RNA fragments were copied into first-strand complementary DNA (cDNA) using reverse transcriptase and random primers. This was followed by second-strand cDNA synthesis using DNA polymerase I and RNase H. The double-stranded cDNA fragments then had the addition of a single "A" nucleotide to prevent self-ligation during the subsequent addition of the indexing adapters. PCR was then used to enrich only those DNA fragments that had adapter molecules on both ends to amplify the amount of DNA in the library. Libraries were validated using Agilent Tape Station High-Sensitivity DNA kits and normalized. Libraries were multiplexed, four samples per lane, and sequenced. Illumina HiSeq 2500 was used to obtain 100 bp singleend reads for samples from the ventral striatum. Illumina HiSeq 2000 was used to obtain 100 bp paired-end reads for samples from the dorsal striatum. 
RNA-seq data quality assessment and differential gene expression (DE) analysis
The fastq files were generat ed by configuring BclToFastq.pl from CASAVA v1.8.2 with the following parameters: -ignore-missing-stats, -ignore-missing-bcl, -ignore-missing-control, -positions-format, clocs, andfastq-cluster-count 350000000. They were then examined using FASTQC (Andrews 2010) . The reads were aligned to the mouse reference genome (version mm10) using a STAR v2.3 (Dobin et al. 2013 ) aligner with default parameters. The alignment results were then evaluated through RNA-SeQC v1.17 (DeLuca et al. 2012) to ensure that all the samples had a consistent alignment rate and no obvious 5′ or 3′ bias. Aligned reads were summarized through featureCounts (Liao et al. 2014 ) with the gene model from Ensemble (Mus_musculus.GRCm38.75.gtf) at the gene level: specifically, the uniquely mapped reads (NH "tag" in bam file) that overlapped with an exon (feature) by at least 1 bp were counted and then the counts of all exons annotated to an Ensemble gene (meta features) were summed into a single number. Only protein coding genes were used for the downstream analysis of this study. To eliminate the between-sample differences in read counts, the summarized counts matrix was then normalized through a set of housekeeping genes Ppia, Gusb, and Gapdh (the sums of the counts are normalized to a fixed number for all samples). Principal component analysis (PCA) was then applied to the normalized count of all the samples from the two brain regions to detect outliers (see Fig. 1 ). DESeq2 (Love et al. 2014 ) was applied to the normalized counts to estimate the fold change between the samples from mice that had self-administered oxycodone and those from yoked saline controls, using negative binomial distribution. An adjusted p value of less than 0.05 (P adj < 0.05) was used to select genes that have a significant expression change.
Gene expression study with qPCR
Samples from the replicate SA study (study 2) were used to confirm expression differences between oxycodone and yoked saline control mice of a subset of randomly selected genes with high and low expression levels in the dorsal and ventral striata, as identified by RNA-seq. We examined genes showing alteration in the expression levels in both the dorsal and ventral striata and also studied genes that were altered in response to oxycodone SA in only one of those brain regions. cDNA was synthesized from 1 μg of total RNA using the SuperScript III first-strand synthesis kit (Invitrogen, Carlsbad, CA). The reaction was performed in an ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA), applying the following program: 2 min at 50°C, 10 min at 95°C, and 40 cycles of 15 s at 95°C and 1 min at 60°C. Sequence Detection software (Applied Biosystems, Foster City, CA) was used to calculate the cycle threshold (Ct) value for each well. Any sample with Ct greater than 35 was not included in the analysis according to the manufacturer's recommendations. The relative expression of each gene was calculated by subtracting the Ct value of the et al. 2014, 2015) .
Statistical analysis on qPCR data
In the qPCR study, the significance of the difference between oxycodone and yoked saline control mice in the expression levels of each gene was evaluated by onetailed t test. A p value of <0.05 was accepted as indicating a significant difference. Adjustment for multiple comparisons (false discovery rate) was performed for the qPCR data.
Gene Ontology analysis
For functional enrichment analyses, DAVID (Ashburner et al. 2000) with default parameters and all mouse genes as a background model was used to test the biological functional enrichment of genes with significant expression changes (P adj < 0.05). The analysis was done through Gene Ontology (GO) (Kanehisa and Goto 2000) and KEGG pathways (Ashburner et al. 2000) . Briefly, DAVID tests the statistical significance of whether the identified genes are over-represented in a specific term (such as GO or KEGG).
Results
Extended access oxycodone self-administration
Self-administration behaviors of oxycodone and yoked saline control mice from study 1 (for the RNA-seq study, also see Zhang et al. 2014 ) and study 2 (for the qPCR study) were similar; we therefore combined the data from the two studies. The nose poking of mice from both SA studies is shown in Mice in the oxycodone group nose poked significantly more at the active hole than at the inactive hole. In contrast, the yoked saline control group did not differ in nose poking between the active and inactive holes. The daily oxycodone intake increased significantly across sessions.
Extended oxycodone self-administration led to transcriptional changes related to inflammation and immune function in the dorsal and ventral striata Dorsal striatum Significant changes were observed in the expression of 55 genes related to inflammation/immune function in the dorsal striatum (Table 1 ), between mice that had self-administered oxycodone and the yoked saline controls. Fifty-four genes in the dorsal striatum showed significant upregulation, whereas one gene showed significant downregulation.
Ventral striatum In the ventral striatum, significant changes in the expression of 141 inflammation/immune-related genes were found between mice that had self-administered oxycodone and the yoked saline controls (Table 2) . Two samples of ventral striatum were not included in the analysis due to their outlier status detected by PCA analysis (see Fig. 1 ). Among the 141 inflammation/immune-related genes, 126 showed significant upregulation after oxycodone SA, whereas 15 genes showed significant downregulation. Thirty-eight genes (labeled with an asterisk) in Tables 1  and 2 were found to be upregulated in both the dorsal and ventral striata, following 14-day extended-access oxycodone SA, compared to the yoked saline control. The heat map in Fig. 3 shows normalized expression of all the differentially expressed inflammation and immune-related genes (p < 0.05) from the dorsal and ventral striata in the oxycodone and yoked saline control mice.
The overlap of inflammation and immune-related genes from the dorsal and ventral striata is shown in the union map (see Fig. 4 ).
Examination of gene expression changes in the dorsal and ventral striata with qPCR qPCR was used to examine the relative messenger RNA (mRNA) levels of a subset of genes identified by RNA-seq in the dorsal striatum (Table 3) , and three genes were found to increase in expression levels in the oxycodone group compared with the yoked saline group as identified by RNA-seq: Fig. 4 A union map shows the overlap between differentially expressed genes from the dorsal and ventral striata. The genes expressed identically in the two brain regions are indicated by the overlap between the two circles Table 3 Confirmation of significant changes in selected inflammation/immune-related genes in the dorsal striatum using qPCR; 6 genes of the 55 found to be changed by RNA-seq were studied Genes are listed by p value a "Yes" indicates that the qPCR replication result was statistically significant and in the same direction. "No" indicates that the qPCR replication result was not statistically significant b From RNA-seq results cytochrome b-245, beta polypeptide (Cybb), proteasome (prosome, macropain) subunit, beta type 9 (large multifunctional peptidase 2) (Psmb9) and solute carrier family 2 (facilitated glucose transporter), and member 1 (Slc2a1). Figure 5 shows the expression levels of these three genes as measured by qPCR. qPCR was used to examine the relative mRNA levels of a subset of genes identified by RNA-seq in the ventral striatum (Table 4) , and four genes were found to increase in expression levels in the oxycodone group compared with the yoked saline group as identified by RNA-seq: cytochrome b-245, beta polypeptide (Cybb), chemokine (C-C motif) receptor type 5 (Ccr5); intercellular adhesion molecule 1 (Icam), and inositol 1,4,5-trisphosphate receptor 1 (Itpr1). Figure 6 shows the expression levels of these four genes measured by qPCR.
The expression levels of three genes in the dorsal striatum and those of seven genes in the ventral striatum were found to be not significantly different between the oxycodone and yoked saline groups, as measured by qPCR. Figure 7 shows the expression levels of these genes.
After adjustment for multiple comparisons of these qPCR data, none of the genes retained an experiment-wise significance.
Enriched function-related gene groups
Thirty GO terms were found to be significantly enriched (Table 5 ). Among these processes are immune response (GO: 0006955), defense response (GO: 0006952), immune effector process (GO: 0002252), and inflammatory response (GO: Fig. 5 Confirmation of mRNA expression changes in the dorsal striatum. qPCR confirmed three upregulated transcripts. The value for each individual sample was determined, and from these individual values, the means and SEMs were calculated. The mean (+SEM) levels of Cybb (a), Psmb9 (b), and Slc2al (c) mRNA levels in the dorsal striatum in mice that had self-administered oxycodone were higher than those of yoked saline controls (n = 7-9/group) Table 4 Confirmation of significant changes in selected inflammation/immune-related genes in the ventral striatum using qPCR; 11 genes of the 141 found to be changed by RNA-seq were studied 
0006954
), suggesting that the expression of inflammatory/ immune-related genes found in this study was altered as a result of chronic oxycodone self-administration. We also found that the genes listed in Tables 1 and 2 were enriched in several immune functions including response to bacterium (GO: 0009617) and defense response to bacterium (GO: 0042742).
Discussion
RNA-seq was used to examine differential gene expression in the dorsal and ventral striata of adult male mice that had undergone 14-day extended-access self-administration of oxycodone, compared with the yoked saline controls. This regimen resulted in substantial daily intake of oxycodone and escalation across sessions. We found here that the mRNA levels of numerous genes related to the inflammation and immune functions changed as a result of oxycodone self-administration, in the dorsal and ventral striata. Early studies revealed that chronic morphine and oxycodone can modulate both adaptive and innate immune systems, as well as activate neuroinflammation (e.g., Cui et al. 2014; Wang et al. 2012) . Acute and chronic morphine administrations showed inhibitory effects on humoral and cellular immune responses (Fecho et al. 1996; Manfredi et al. 1993; Novick et al. 1989; West et al. 1998) . In contrast, one study found that hydromorphone and oxycodone were not immunosuppressive and may act as immune stimulants (e.g., Sacerdote et al. 1997) . In our prior hypothesis-based qPCR studies, we did not examine whether oxycodone SA affected the expression of genes related to inflammation and immune functions (Mayer-Blackwell et al. 2014; Zhang et al. 2014 Zhang et al. , 2015 . One study had examined the effect of chronic highdose experimenter-administered oxycodone on gene expression in whole rat brain and found that this led to changes in the expression of the following immune function-related genes: Hla-dra, CD163, Lims2, Dsipi, Cklfsf6, and Tnfrsf11b (Hassan et al. 2007 ). However, it is unknown which brain region(s) were involved in these effects, and whether these or other changes would be observed in animals selfadministering oxycodone.
In the current study, we observed changes in the expression levels of numerous genes related to inflammation and immune functions following oxycodone SA. For example, a significant increase in mRNA for Ccr5 was found in this study. Ccr5 are seven-transmembrane G protein-coupled receptors that associate with Gi/Go (Raport et al. 1996) . Ccr5 regulates chemotaxis and cell activation via interactions with several Fig. 6 Confirmation of mRNA expression changes in the ventral striatum. qPCR confirmed upregulated transcripts of Ccr5 (a), Cybb (b), Icam (c), and Itpr1 (d) in mice that had selfadministered oxycodone compared to the yoked saline controls (n = 7-9/group) chemokine ligands (Allen et al. 2007 ). Ccr5 is expressed by several cell types including lymphocytes, microglia, and astrocytes, as well as neurons in the brain (Sorce et al. 2011; Westmoreland et al. 2002) . Several in vitro experiments have shown an increase in Ccr5 expression following 24-48 h of morphine exposure in primary normal human astrocytes (Mahajan et al. 2005; Mahajan et al. 2002) and human lymphocytic CEMx174 cells (Miyagi et al. 2000; Suzuki et al. 2002a, b) . Co-immunoprecipitation studies have shown that Ccr5 heterodimerizes with MOP-r opioid receptors (Chen et al. 2004) . Further, heterologous cross-deactivation of the MOP-r and Ccr5 has been shown in both in vivo and in vitro experiments (Szabo et al. 2003) .
Ccr5 plays an important role in HIV infection in humans. Individuals with the Ccr5 variant, 32 bp deletion, thus without functional Ccr5 protein, are highly resistant to HIV infection and show delayed progression to AIDS (Alkhatib and Berger 2007; Kaslow et al. 2005) . Genetic modification in Ccr5 gene results in HIV resistance in T cells (Romano Ibarra et al. 2016) . Pharmacological blockade of Ccr5 inhibits the entry of HIV viruses into target cells (e.g., Romano Ibarra et al. 2016) . The Ccr5 antagonists maraviroc and cenicriviroc are used not only for the treatment of HIV infection but also for improving impairment in HIV-related cognitive function (e.g., Gates et al. 2016; Kim et al. 2016; Kramer et al. 2014; Ndhlovu et al. 2014) .
The observed increase in Ccr5 mRNA following 14-day oxycodone self-administration extends the in vitro findings of protracted exposure to MOP-r agonists resulting in increased Ccr5 expression. Further experiments are needed to examine the mechanism by which oxycodone self-administration results in increased Ccr5 mRNA expression and whether activity at Ccr5 influences the escalation of oxycodone self-administration.
It is postulated that the gene expression changes in the brains of mice that had self-administered oxycodone were initiated by microglia. Microglia represent 10-15% of all cells found within the brain (Lawson et al. 1992) . Microglia are extremely sensitive to small changes in the microenvironment and are activated by various factors such as proinflammatory cytokines, necrosis factors, and changes in extracellular potassium (e.g., Aloisi 2001; Brown et al. 1998; Kust et al. 1997; Tooyama et al. 2002) . Recent neuroimaging studies have detected microglial activation in the brains of rats exposed to Fig. 7 The expression levels of genes that were found to be not significantly different between oxycodone and yoked saline control groups as measured by qPCR were shown in a for the dorsal striatum and in b for the ventral striatum repeated morphine administration (Auvity et al. 2016) . We therefore hypothesize that in response to persistent MOP-rmediated activity caused by oxycodone, microglia may proliferate and become activated. The involvement of microglia in the activation of immune-related genes in the brain following chronic oxycodone self-exposure could be of interest in future studies.
Like macrophages in the periphery, microglia secrete inflammatory mediators to orchestrate the immune response in the brain. Using RNA-seq, we have found upregulation of the expression of genes encoding for interleukin-1 beta (Il1b), monocyte chemotactic protein-5 (Ccl12), tumor necrosis factors (Tnfaip2), and interferon gamma-induced GTPase (Igtp), which may play important roles in proinflammatory functions.
The immune systems modulate a variety of brain functions and affect behaviors (Boulanger 2009; Miller et al. 2013) . Prescription opioids such as oxycodone are thought to initiate their reward-related effects by acting as MOP-r agonists and also by subsequently increasing dopamine in the mesolimbic and nigrostriatal dopaminergic pathways (Di Chiara and Imperato 1988a, b) . However, recent studies suggest that innate immune signaling in the brain also plays an important role in the rewarding properties of opioids. For example, suppression of glial proinflammatory responses by AV411, a glial inhibitor, significantly reduced morphine or oxycodone withdrawal, while improving analgesia ) and blocking morphine-induced increases of dopamine in the nucleus accumbens (Bland et al. 2009 ). Thus, whether inflammation and immune responses are involved in the escalation of oxycodone self-administration and development of vulnerability to oxycodone addiction will be an important area of future study. We identified expression changes in a large number of inflammation/immune-related genes in this study after chronic oxycodone SA, in the absence of provoked bacterial and viral infections. These altered inflammation/immune systems were found in the terminal regions of the nigrostriatal and mesolimbic dopaminergic pathways (e.g., Lindvall et al. 1984; Skagerberg et al. 1984) . Future studies could determine whether alterations in inflammation/immune-related genes and gene products are involved in the rewarding properties of oxycodone or in the escalation of oxycodone self-administration. The potential impact of prescription opioid exposure on these inflammation/immune-related gene targets in the context of clinical analgesia is also a potential area for further study.
Since gene expression changes were examined immediately after 14 consecutive days of chronic oxycodone self-administration, it is unknown whether such alterations occurred immediately after one session of oxycodone self-administration or resulted from chronic oxycodone self-administration exposure or from escalation of intake. It is also not clear whether the changes in inflammation/immune-related gene expression are long-lasting, which may play an important role in the development of sensitivity to oxycodone upon re-exposure (relapse) or during withdrawal. Further studies could also determine whether similar changes also occur in other brain regions or in the peripheral nervous system.
Conclusion
We found here, using an unbiased RNA-seq approach, that chronic oxycodone SA resulted in alterations in multiple inflammatory and immune-related genes in the dorsal and ventral striata. Some human studies also report changes in various immune and inflammatory mediators, in the brain of persons with chronic heroin exposure (Neri et al. 2013) .
The role of neuroinflammatory processes and immune response in the effects of opioids (to either heroin or prescription opioids such as oxycodone) is not well understood. Overall, the present study on the transcriptome provides an initial set of targets and gene systems to examine how the brain inflammatory and immune gene systems are affected by chronic selfadministration of the widely abused prescription opioid oxycodone.
